JP2017523984A5 - - Google Patents

Download PDF

Info

Publication number
JP2017523984A5
JP2017523984A5 JP2017506286A JP2017506286A JP2017523984A5 JP 2017523984 A5 JP2017523984 A5 JP 2017523984A5 JP 2017506286 A JP2017506286 A JP 2017506286A JP 2017506286 A JP2017506286 A JP 2017506286A JP 2017523984 A5 JP2017523984 A5 JP 2017523984A5
Authority
JP
Japan
Prior art keywords
antibody
seq
pharmaceutical composition
ox40l
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017506286A
Other languages
English (en)
Japanese (ja)
Other versions
JP6628787B2 (ja
JP2017523984A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/043408 external-priority patent/WO2016022468A1/en
Publication of JP2017523984A publication Critical patent/JP2017523984A/ja
Publication of JP2017523984A5 publication Critical patent/JP2017523984A5/ja
Application granted granted Critical
Publication of JP6628787B2 publication Critical patent/JP6628787B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017506286A 2014-08-04 2015-08-03 拮抗性抗ｏｘ４０ｌ抗体およびそれらの使用方法 Active JP6628787B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462032959P 2014-08-04 2014-08-04
US62/032,959 2014-08-04
PCT/US2015/043408 WO2016022468A1 (en) 2014-08-04 2015-08-03 Antagonistic anti-ox40l antibodies and methods of their use

Publications (3)

Publication Number Publication Date
JP2017523984A JP2017523984A (ja) 2017-08-24
JP2017523984A5 true JP2017523984A5 (https=) 2018-08-30
JP6628787B2 JP6628787B2 (ja) 2020-01-15

Family

ID=55264394

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017506286A Active JP6628787B2 (ja) 2014-08-04 2015-08-03 拮抗性抗ｏｘ４０ｌ抗体およびそれらの使用方法

Country Status (7)

Country Link
US (2) US10167339B2 (https=)
EP (1) EP3194445A4 (https=)
JP (1) JP6628787B2 (https=)
CN (1) CN107074951B (https=)
AU (1) AU2015301338C1 (https=)
IL (1) IL250428B (https=)
WO (1) WO2016022468A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9512229B2 (en) 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
US9434785B1 (en) 2015-04-30 2016-09-06 Kymab Limited Anti-human OX40L antibodies and methods of treating graft versus host disease with the same
US20220372153A1 (en) * 2015-03-03 2022-11-24 Kymab Limited Synergistic combinations of ox40l antibodies for the treatment of gvhd
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018170764A1 (zh) * 2017-03-22 2018-09-27 深圳市博奥康生物科技有限公司 一种用于 RNAi 的载体及其应用
SMT202600062T1 (it) * 2017-10-18 2026-03-09 Alpine Immune Sciences Inc Proteine immunomodulatrici del ligando di icos variante e composizioni e metodi correlati
CN108458964A (zh) * 2017-10-31 2018-08-28 天津协和华美医学诊断技术有限公司 一种抗体组合物及其在淋巴浆细胞性淋巴瘤微小残留检测中的应用
KR20210138674A (ko) * 2019-03-12 2021-11-19 유니버시티 헬스 네트워크 Tsg-6 항체 및 그 용도
PH12022551231A1 (en) * 2019-12-06 2023-07-31 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l
IL297538A (en) * 2020-04-24 2022-12-01 Millennium Pharm Inc Anti-cd19 antibodies and uses thereof
KR102705172B1 (ko) * 2020-12-09 2024-09-11 에이치케이이노엔 주식회사 항 OX40L 항체, 항 OX40L 및 항 TNFα 이중 특이성 항체 및 이들의 용도
JP7688150B2 (ja) * 2020-12-09 2025-06-03 エイチケー イノ．エヌ コーポレーション 抗ＯＸ４０Ｌ抗体、抗ＯＸ４０Ｌ及び抗ＴＮＦαの二重特異性抗体、並びにこれらの用途
MX2024001877A (es) * 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.
KR20260047587A (ko) * 2023-08-04 2026-04-08 포르비타 바이오로직스 인코포레이티드 항-ox40l 항체 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3914342B2 (ja) * 1997-09-25 2007-05-16 武田薬品工業株式会社 ｇｐ３４結合阻害物を有効成分として含有する医薬組成物
US7291331B1 (en) * 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
TWI309240B (en) * 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
RU2426744C2 (ru) * 2005-12-16 2011-08-20 Дженентек, Инк. Антитела к ox40l и способы их применения
EP2513145B1 (en) * 2009-12-14 2018-01-24 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
US20120020960A1 (en) 2010-07-26 2012-01-26 Baylor Research Institute Thymic Stromal Lymphopoietin (TSLP) and OX40 Ligand in Cancer

Similar Documents

Publication Publication Date Title
JP2017523984A5 (https=)
JP2012501669A5 (https=)
CA3036912C (en) Antibody specifically binding to pd-1 and functional fragment thereof
JP2012501670A5 (https=)
JP2019527553A5 (https=)
JP2017531427A5 (https=)
JP2019535670A5 (https=)
RU2018124602A (ru) Новые анти-pd-l1 антитела
JP2011509245A5 (https=)
TW201833141A (zh) 抗b7-h3抗體、其抗原結合片段及其醫藥用途
IL261666B1 (en) Binding proteins and methods of use thereof
RU2018108048A (ru) Новые анти-pd-1 антитела
JP2018516853A5 (https=)
JP2017149720A5 (https=)
JP2021530244A5 (https=)
JP2012525829A5 (https=)
JP2011207882A5 (https=)
JP2014529590A5 (https=)
JP2011527899A5 (https=)
JP2024029261A5 (https=)
JP2021502984A5 (https=)
AU2018263196A1 (en) Anti-interferon gamma antibodies and uses thereof
US12037390B2 (en) Leptin antibodies and method of reducing leptin
JP2021518137A5 (https=)
CN104955846B (zh) 人源化抗hmgb1抗体或其抗原结合性片段